Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Aptiv Solutions Improves Accuracy of Dose Escalation Studies with Launch of ADDPLAN® DF 3.0

Published: Friday, May 16, 2014
Last Updated: Friday, May 16, 2014
Bookmark and Share
ADDPLAN® DF 3.0 incorporates complex statistical methodologies to prevent under and over-estimation of a therapeutic’s maximum target dose (MTD) during Phase I dose escalation trials.

Accurate estimation of MTD minimises safety and efficacy issues leading to late phase clinical trial failures and is of particular importance for oncology, which has one of the highest Phase III attrition rates among all major therapeutic classes.

“Inaccurate dose selection in Phase I can place a ceiling on drug efficacy in all subsequent phases, potentially dooming a good drug, or expose patients to needlessly high and harmful doses. Operational tools that improve accuracy of Phase I trials is a major objective for drug developers,” says Professor Andy Grieve, Senior Vice President of Clinical Trial Methodology at Aptiv Solutions.

The pharmaceutical industry is well aware that the traditional 3+3 approach, which is still used in more than 95% of Phase I trials, is slow and often underestimates the MTD. Alternative model-based approaches, such as the continual reassessment method (CRM) and the modified toxicity probability interval (mTPI) approach, have broader appeal. Regulatory agencies are supportive of the development of innovative dose escalation procedures. For example, Sue-Jane Wang of the Office of Biostatistics at the FDA co-authored a recent publication in the Journal of Clinical Oncology on the mTPI methodology.

Despite clear advantages, adoption of these model-based approaches has been slow due to the intensive programming required for confident implementation and avoidance of MTD over-estimation. Aptiv Solutions developed ADDPLAN DF 3.0 to provide a validated platform for simulating and comparing dose escalation designs without the need for intensive programming. The software, which benefited from beta testing feedback from ADDPLAN DF Consortium members at Eli Lilly, Janssen, and Novartis, simulates and allows comparison of the 3+3, mTPI, classical CRM, and a modified CRM approach known as Bayesian logistic regression with overdose control. The latter methodology was originally developed by Novartis.

“Several dose escalation methods exist but without a tool to compare these methods, the effectiveness of Phase I studies is significantly reduced. Simulations comparing the impact of dose-response assumptions, dose selection rules, and stopping rules increase the transparency of these methods and help statisticians select the appropriate dose escalation design,” says Grieve. “ADDPLAN DF 3.0 is a robust tool to help resolve dose-related drug failures and supports the industry’s push to adopt innovative design and execution strategies to improve drug development.” 

Executing adaptive designs in Phase I and beyond can require sophisticated logistics and robust firewalls to maintain trial integrity. ADDPLAN DF software provides direct integration with AptivAdvantage®, the leading real-time execution technology platform for seamless implementation of dose adaptations and operational modifications in adaptive design trials.

In addition to its utility for Phase I studies, ADDPLAN DF is the first validated software to utilise the EMA-qualified MCP-Mod methodology for more accurate analysis of Phase II dose-finding designs. The ADDPLAN DF Consortium members are currently collaborating to develop the first toolset for applying the MCP-Mod methodology to adaptive trial designs, expected in late 2014. 

Earlier this year, the FDA, EMA, and PMDA licensed the ADDPLAN family of innovative software for the design, simulation, and analysis of adaptive clinical trials. 

The ADDPLAN DF development team, led by Grieve, has published a white paper on Phase I dose escalation designs, titled “ADDPLAN® DF for Designing More Accurate Dose Escalation Studies in Exploratory Drug Development,” that is available below.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Friday, May 24, 2013
Aptiv Solutions Growing: Opens New Office in North Carolina
New office is located at 4505 Emperor Boulevard in the Imperial Center.
Monday, December 10, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos